PF-Atlas › Clinical Trials › NCT04739761
A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer
Trastuzumab Deruxtecan · Phase 3
Registry ID
NCT04739761
Phase
Phase 3
Status
Active, not recruiting
Drug / intervention
Trastuzumab Deruxtecan
Sponsor
AstraZeneca
Start
2021-06-22
About this trial
Trastuzumab Deruxtecan is evaluated in NCT04739761, a Phase 3 idiopathic pulmonary fibrosis study sponsored by AstraZeneca. Current status: Active, not recruiting.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT04739761 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.